This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Pulmonary disease				
Cystic fibrosis (CF)	Golgi reassembly stacking protein 2 55 kDa (GORASP2; GRASP55); cystic fibrosis transmembrane conductance regulator (CFTR)	Cell culture and mouse studies suggest upregulating GRASP55 could help treat CF. In a mouse model of CF caused by the F508 deletion variant of <i>Cftr</i> , overexpression of <i>Grasp55</i> increased survival compared with normal <i>Grasp55</i> expression. Next steps include screening for agents that can increase GRASP55 levels. Vertex Pharmaceuticals Inc's VX-770 and VX-809, small molecule CFTR stabilizers, are in Phase III and II testing, respectively, to treat CF. SciBX 4(36); doi:10.1038/scibx.2011.1022 Published online Sept. 15, 2011	Patent and licensing status undisclosed	Gee, H.Y. <i>et al. Cell</i> ; published online Sept. 2, 2011; doi:10.1016/j.cell.2011.07.021 Contact: Min Goo Lee, Yonsei University College of Medicine, Seoul, South Korea e-mail: mlee@yuhs.ac